Tag: Cancer: Prostate
10-Year Outcomes Similar for H-IMRT, C-IMRT in Prostate Cancer
10-year cumulative incidence of biochemical and/or clinical disease failure no different with C-, H-IMRT
Combined Biopsy Method Better for Prostate Cancer Diagnosis
Cancer diagnosed in 9.9 percent more, upgrading seen in 21.8 percent with MRI-targeted + systematic biopsy
Surgical Approach Not Tied to Decision Regret After Prostatectomy
Functional and oncologic outcomes, autonomous decision-making, and follow-up time influence regret
Statin Use May Reduce Mortality in High-Risk Prostate Cancer
Statin use alone or in combination with metformin tied to lower all-cause, prostate cancer mortality
Functional Outcomes Similar Across Localized Prostate Cancer Treatments
However, incontinence and sexual function are worse five years following prostatectomy
Outcomes No Worse for Black Veterans With Prostate Cancer
For men in VA health system, blacks do not present with more advanced disease or have higher mortality
Intensity-Modulated Radiation Charges for Prostate Cancer Vary
Mean charge for standard 28-fraction was $111,728.80, 10.1 times the price paid by Medicare
Increasing Vegetable Intake Does Not Slow Prostate Cancer
Behavioral intervention had no impact on time to progression among men with early-stage disease
AI System Can Detect, Grade Cancer in Prostate Needle Biopsy
AUCs were 0.997, 0.986 for distinguishing between benign, malignant biopsy cores, respectively
Risk-Based Approach Could Help Target Prostate Cancer Screening
Risk-based screening yields less overdiagnosis, more cost-effective than age-based screening
